Beam Therapeutics Inc.
BEAMBiotechnology
$27.23−5.58%As of Oct 30vs prior close
- Market cap
- $2.8B
- P/E (TTM)
- –
- From 52W high
- −28.19%
- EPS (LTM)
- -$0.67
- Revenue (LTM)
- $156M
- Net margin
- -55.45%
- Dividend yield
- 0.00%
Nomior Score
37
Steady ProfileSpeculativeBottom 24% of the scored universe
Growth50
Quality48
Value43
Momentum42
Resilience31
Growth
+344.98%revenue a year over 6 fiscal years
YE19 $18KLTM $156M
Connections
Revenue to profitQ2 YE26
The operating loss was 25827% of revenue, wider by 24408 pts on a year.
Who owns it
2funds, 1 tracked portfolio